ARTICLE | Top Story
Dupilumab hits marks in Phase III dermatitis trials
April 2, 2016 12:09 AM UTC
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) said dupilumab ( REGN668) met the primary endpoint in two identical Phase III trials to treat moderate to severe atopic dermatitis. Compared with placebo, dupilumab significantly increased the proportion of patients achieving clearing or near-clearing of skin lesions as measured by an Investigator's Global Assessment (IGA) score of 0-1.
On Friday, Regeneron gained $44.81 (12%) to $405.25 on the news. ...